Montgomery William, Kadziola Zbigniew, Ye Wenye, Xue Hai Bo, Liu Li, Treuer Tamás
Global Patient Outcomes and Real World Evidence, Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia.
Real World Analytics Capabilities, Eli Lilly GmbH, Vienna, Austria.
Neuropsychiatr Dis Treat. 2015 Jan 19;11:177-83. doi: 10.2147/NDT.S73992. eCollection 2015.
The aim of this study was to investigate the correlation between changes in symptoms and changes in self-reported quality of life among Chinese patients with schizophrenia who were switched from a typical antipsychotic to olanzapine during usual outpatient care.
This post hoc analysis was conducted using data from the Chinese subgroup (n=475) of a multicountry, 12-month, prospective, noninterventional, observational study. The primary publication previously reported the efficacy, safety, and quality of life among patients who switched from a typical antipsychotic to olanzapine. Patients with schizophrenia were included if their symptoms were inadequately controlled with a typical antipsychotic and they were switched to olanzapine. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impressions-Severity scale (CGI-S). Health-Related Quality of Life (HRQOL) was assessed using the World Health Organization Quality of Life-Abbreviated (WHOQOL-BREF). Paired t-tests were performed to assess changes from baseline to endpoint. Pearson's correlation coefficients (r) were used to assess the correlations between change in symptoms (BPRS and CGI-S scores) and change in HRQOL (WHOQOL-BREF scores).
Symptoms and HRQOL both improved significantly over the 12 months of treatment (P<0.001). Significant correlations were observed between changes from baseline to end of study on the BPRS and the CGI-S and each of the WHOQOL-BREF four domain scores and two overall quality-of-life questions. The correlation coefficients ranged from r=-0.45 to r=-0.53 for the BPRS and WHOQOL-BREF. The correlation coefficients were slightly smaller between the CGI-S and WHOQOL-BREF, ranging from r=-0.33 to r=-0.40.
For patients with schizophrenia, assessing quality of life has the potential to add valuable information to the clinical assessment that takes into account the patient's own perspective of well-being.
本研究旨在调查在常规门诊护理期间从典型抗精神病药物换用奥氮平的中国精神分裂症患者的症状变化与自我报告的生活质量变化之间的相关性。
本事后分析使用了一项多国家、为期12个月的前瞻性、非干预性观察性研究的中国亚组（n = 475）的数据。该主要出版物先前报告了从典型抗精神病药物换用奥氮平的患者的疗效、安全性和生活质量。如果精神分裂症患者使用典型抗精神病药物症状控制不佳且换用奥氮平，则纳入研究。使用简明精神病评定量表（BPRS）和临床总体印象-严重程度量表（CGI-S）测量症状严重程度。使用世界卫生组织生活质量简表（WHOQOL-BREF）评估健康相关生活质量（HRQOL）。进行配对t检验以评估从基线到终点的变化。使用Pearson相关系数（r）评估症状变化（BPRS和CGI-S评分）与HRQOL变化（WHOQOL-BREF评分）之间的相关性。
在12个月的治疗期间，症状和HRQOL均有显著改善（P<0.001）。在从基线到研究结束时BPRS和CGI-S的变化与WHOQOL-BREF四个领域评分中的每一个以及两个总体生活质量问题之间均观察到显著相关性。BPRS与WHOQOL-BREF之间的相关系数范围为r = -0.45至r = -0.53。CGI-S与WHOQOL-BREF之间的相关系数略小，范围为r = -0.33至r = -0.40。
对于精神分裂症患者，评估生活质量有可能为考虑患者自身幸福感观点的临床评估增添有价值的信息。
